Related Experiment Video

Updated: May 23, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Metformin and pancreatic cancer: a clue requiring investigation

Michael Pollak1

  • 1Department of Oncology, Lady Davis Institute for Medical Research of the Jewish General Hospital and McGill University, Montreal, Quebec, Canada. michael.pollak@mcgill.ca

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|April 3, 2012
PubMed

Insights

Metformin shows potential anticancer effects in lab studies and in diabetic patients. Further research is needed to confirm its efficacy and safety for cancer treatment before it can be repurposed.

Area of Science:

  • Oncology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Laboratory research indicates metformin possesses antineoplastic properties under specific conditions.
  • Epidemiological studies suggest a potential reduction in cancer incidence among diabetic individuals using metformin.
  • Growing scientific interest surrounds the hypothesis of metformin's anticancer activity.

Purpose of the Study:

  • To explore the potential of repurposing metformin as an anticancer agent.
  • To identify and address existing knowledge gaps regarding metformin's oncologic applications.

Main Methods:

  • Review of laboratory models demonstrating metformin's antineoplastic effects.
  • Analysis of pharmacoepidemiologic data on metformin use and cancer burden in diabetic populations.

Main Results:

  • Consistent evidence from laboratory settings suggests metformin's anticancer activity.
  • Observational studies indicate a possible link between metformin use and decreased cancer burden in diabetics.

Conclusions:

  • Metformin exhibits promising antineoplastic activity in preclinical and observational studies.
  • Significant knowledge gaps remain, necessitating further investigation before clinical repurposing for oncologic indications.

More Related Videos

Dissection of the Mouse Pancreas for Histological Analysis and Metabolic Profiling08:21

Dissection of the Mouse Pancreas for Histological Analysis and Metabolic Profiling

Published on: August 19, 2017

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma05:44

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Published on: November 5, 2020

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Chronic Pancreatitis I: Introduction01:25

Chronic Pancreatitis I: Introduction

Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...